{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"12","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"740"}],"units":"Participants"}],"description":"Treatment duration was defined as the time between the first and the last infusion of trastuzumab emtansine.","dispersionType":"Full Range","groups":[{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab Emtansine"}],"paramType":"MEDIAN","populationDescription":"SE population included all randomized participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 12 months","title":"Median Duration of Trastuzumab Emtansine Exposure","type":"SECONDARY","unitOfMeasure":"months"}